Your search returned 5 results.

Results
	1.	The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. MedStar authors: Swain, Sandra M PMID: 26759246 Year: 2016 Citation: Breast Cancer Research & Treatment. 155(2):235-51, 2016 Jan. Institution: Washington Cancer Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Amiri-Kordestani L, Chavez KJ, Conway CM, Dine JL, Greer YE, Hewitt SM, Lipkowitz S, Merchant AS, O'Sullivan CC, Sinclair S, Steinberg SM, Stone B, Swain SM, Voeller D Add to cart (remove)
	2.	Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC. MedStar authors: Gallagher, Christopher Lynce, Filipa Ottaviano, Yvonne PMID: 34400413 Year: 2021 Citation: Clinical Cancer Research. 27(21):5810-5817, 2021 11 01. Institution: MedStar Franklin Square Medical Center Washington Cancer Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Althouse SK, Ballinger TJ, Bauchle A, Dong Z, Gallagher C, Liu JY, Lynce F, Masters AR, Miller KD, Ottaviano YL, Perkins SM, Sardesai SD, Schneider BP, Storniolo AM, Stratford RE Jr, Thomas A, Zhang JT DOI: https://dx.doi.org/10.1158/1078-0432.CCR-21-0493 Add to cart (remove)
	3.	Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. MedStar authors: Chitalia, Ami Gallagher, Christopher Schlam, Ilana Swain, Sandra M Tiwari, Shruti PMID: 38538574 Year: 2024 Citation: Nature communications . 15(1):2691, 2024 Mar 27. Institution: Washington Cancer Institute Department: Associate Dean for Research Development MedStar Health Medline publication type: Clinical Trial, Phase II Journal Article Randomized Controlled Trial Form of publication: Journal Article All authors: Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C DOI: https://dx.doi.org/10.1038/s41467-024-46961-x Add to cart (remove)
	4.	What Proportion of BRCA-Associated Breast Cancer Is Human Epidermal Growth Factor 2-Low and Eligible for Additional Targeted Therapy?. MedStar authors: Whitaker, Kristen PMID: 38776577 Year: 2024 Citation: Journal of Surgical Research. 299:217-223, 2024 Jul. Institution: MedStar Washington Hospital Center Department: Hematology/Oncology Medline publication type: Journal Article Form of publication: Journal Article All authors: Forester E, Belsare A, Kim DW, Whitaker K, Obeid E, Goldstein LJ, Bleicher RJ, Daly MB, Williams AD DOI: https://dx.doi.org/10.1016/j.jss.2024.04.032 Add to cart (remove)
	5.	IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer. MedStar authors: Swain, Sandra M MedStar Health PMID: 38755096 Year: 2024 Citation: Annals of Oncology. 35(7):630-642, 2024 Jul. Department: Associate Dean for Research Development Medline publication type: Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Form of publication: Journal Article All authors: Dent R, Andre F, Goncalves A, Martin M, Schmid P, Schutz F, Kummel S, Swain SM, Bilici A, Loirat D, Villalobos Valencia R, Im SA, Park YH, De Laurentis M, Colleoni M, Guarneri V, Bianchini G, Li H, Kirchmayer Machackova Z, Mouta J, Deurloo R, Gan X, Fan M, Mani A, Swat A, Cortes J DOI: https://dx.doi.org/10.1016/j.annonc.2024.04.001 Add to cart (remove)

Powered by Koha